Neuroleptic-induced parkinsonism in Alzheimer's disease

Psychiatric Annals

Volumn 32, Issue 4, 2002, Pages

  Mamo, David C ^a   Sweet, Robert A ^a,b   Mulsant, Benoit H ^a   Rosen, Jules ^a   Pollock, Bruce G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; HOMOVANILLIC ACID; LORAZEPAM; NEUROLEPTIC AGENT; NORTRIPTYLINE; PERPHENAZINE;

AGING; ALZHEIMER DISEASE; BEHAVIOR DISORDER; BRADYKINESIA; DELUSION; DOPAMINE METABOLISM; DOSE RESPONSE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; HALLUCINATION; HUMAN; LEWY BODY; MAJOR DEPRESSION; METABOLITE; MORBIDITY; MORTALITY; PARKINSONISM; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; URINE INCONTINENCE;

EID: 0242382823     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20020401-10     Document Type: Review

References (20)

1. Tariot PN, Blazina L. The pathophysiology of dementia. In: Morriss JC, ed. Handbook of Dementing Illnesses. New York, NY: Marcel Dekker; 1994:461-475.
2. U.S. Department of Health and Human Services. State Operations Manual: Provider Certification in Health Care Financing Administration. 1992.
3. Gottlieb GL, McAllister TW, Gur RC. Depot neoroleptics in the treatment of behavioral disorders in patients with Alzheimer's disease. J Am Geriatr Soc. 1988;36:619-621.
4. Steele C, Lucas MJ, Tune L. Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the Alzheimer's type: preliminary findings. J Clin Psychiatry. 1986;47:310-312.
5. Devanand DP, Sackeim HA, Brown RP, Mayeux R. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol. 1989;46:854-857.
6. Sweet RA, Pollock BG, Mulsant BH, et al. Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report. Biol Psychiatry. 1997;42:1016-1023.
7. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990;38:553-563.
8. Sweet RA, Akil M, Mulsant BH, Ulrich R, Pasternak RE, Zubenko GS. Determinants of spontaneous extrapyramidal symptoms in elderly psychiatric inpatients diagnosed with Alzheimer's disease, major depressive disorder, or psychotic disorder. J Neuropsychiatry Clin Neurosci. 1998;10:68-77.
9. Funkenstein HH, Albert MS, Cook NR, et al. Extrapyramidal signs and other neurological findings in clinically diagnosed Alzheimer's disease: a community-based study. Arch Neurol. 1993;50:51-56.
10. Sweet RA, Mulsant BH, Pollock BG, Rosen J, Altieri LP. Neuroleptic-induced parkinsonism in elderly patients diagnosed with psychotic major depression and dementia of the Alzheimer's type. Am J Geriatr Psychiatry. 1996;4:311-319.
11. Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology. 1990;40:1-8.
12. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992;305:673-678.
13. Weiner MF, Risser RC, Cullum CM, et al. Alzheimer's disease and its Lewy body variant: a clinical analysis of postmortem verified cases. Am J Psychiatry. 1996;153:1269-1273.
14. Kaye JA, May C, Daly E, et al. Cerebrospinal fluid monoamine markers are decreased in dementia of the Alzheimer type with extrapyramidal features. Neurology. 1988;38:554-557.
15. Perry EK, Marshall E, Perry RH, et al. Cholinergic and dopaminergic activities in senile dementia of Lewy body type. Alzheimer Dis Assoc Disord. 1990;4:87-95.
16. Murray AM, Weihmueller FB, Marshall JF, Hurtig HI, Gottleib GL, Joyce JN. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann Neurol. 1995;37:300-312.
17. Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E. Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology. 1993;43:1927-1934.
18. Joyce JN, Murray AM, Hurtig HI, Gottlieb GL, Trojanowski JQ. Loss of doparnine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease. Neuropsychopharmacology. 1998;19:472-480.
19. Seeman P. Dopamine receptors in human brain diseases. In: Creese J, Fraser CM, eds. Dopamine Receptors: Receptor Biochemistry and Methodology. New York, NY: Alan R. Liss; 1987:233-245.
20. Perry E, Court J, Goodchild R, et al. Clinical neurochemistry: developments in dementia research based on brain bank material. J Neural Transm. 1998;105:915-933.